Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

VX135 + Ribavirin: Enrollment in one study is

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jq1234 Member Profile
Member Level 
Followed By 48
Posts 3,859
Boards Moderated 0
Alias Born 12/13/09
160x600 placeholder
U.S. Stocks Struggle To Retain Record Levels
U.S. stocks pared most of their early morning gains on Friday as the rally triggered by a fresh dose of liquidity from China's central bank and dovish comments from European Central Bank President Mario Draghi faded by afternoon.
Top Equities Stories Of The Day
China Mobile's Need for Speed -- Barron's Asia
Intel Projects More Growth in 2015 -- Update
Zoetis Unveils $500 Million Stock Buyback Plan -- Update
Technip Bids for CGG -- 2nd Update
Appeals Court Grants TV Programmers Stay in FCC Dispute -- Update
European Telecoms Bet on Data, Investment in 4G Infrastructure
Merrill Loses Veteran Wealth Manager to UBS -- Street Moves
Chinese Premier Plays Down Qualcomm's Woes
jq1234 Member Level  Tuesday, 04/30/13 06:49:53 PM
Re: DewDiligence post# 160555
Post # of 184115 
VX135 + Ribavirin: Enrollment in one study is complete, expect data 2nd half this year. I suppose most likely at AASLD in Nov.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist